SARS-CoV-2 vaccines: a triumph of science and collaboration
Roughly 1 year after the first case of COVID-19 was identified and less than 1 year after the sequencing of SARS-CoV-2, multiple SARS-CoV-2 vaccines with demonstrated safety and efficacy in phase III clinical trials are available. The most promising vaccines have targeted the surface glycoprotein (S...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical investigation
2021-05-01
|
| Series: | JCI Insight |
| Online Access: | https://doi.org/10.1172/jci.insight.149187 |